Role of cytogenetic profiles as prognostic factors for complete remission after induction phase in acute myeloblastic leukemia

Hikari Ambara Sjakti; Gatot Djajadiman; Pustika Amalia Wahidiyat; Agus Kosasih; Iswari Setianingsih

doi:10.14238/pi61.6.2021.343-9

Hikari Ambara Sjakti epartment of Pediatric Hematology-Oncology, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
Gatot Djajadiman epartment of Pediatric Hematology-Oncology, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
Pustika Amalia Wahidiyat epartment of Pediatric Hematology-Oncology, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
Agus Kosasih Dharmais Cancer Center Hospital, Jakarta, Indonesia
Iswari Setianingsih Eijkman Institute for Molecular Biology, Jakarta, Indonesia

DOI: https://doi.org/10.14238/pi61.6.2021.343-9

Keywords: t(8;21), inv(16), acute myeloid leukemia, prognostic, cytogenic

Abstract

Background Risk stratification for acute myeloid leukemia (AML) in children is a must in treatment strategy. This stratification is based on cytogenetic profiles, which are needed to determine proper management to gain better outcomes and reduce side effects of treatment. There is no such risk stratification available in Indonesia until now.

Objective To evaluate the association between cytogenetic profiles of t(8,21) and inv(16) mutations with the complete response to induction phase of chemotherapy in pediatric AML.

Methods A prospective study was conducted between year 2018 and 2020, involving children with AML from 4 pediatric oncology centers in Jakarta. Subjects were evaluated for cytogenetic profiles, especially t(8,21) and inv(16), as the favorable predictors for AML. Bone marrow remission was evaluated after 2 cycles of induction phase. The results were evaluated for remission rate and survival analysis.

Results Karyotype data of 18 subjects were obtained. Translocation t(8;21) detected in 1 subject, and inv(16) mutation in 4 subjects. These two variables had no significant correlation with complete remission after induction phase. Nevertheless, favorable group had more tendencies to achieved remission than unfavorable group. Complete remission achieved in 61% subjects, 90% of theme had a relapse period with an average time 43 weeks. The relapse period in favorable group was shoter than in unfavorable group (34 weeks and 44 weeks, respectively).

Conclusions This study shows that cytogenetic profiles of t(8;21) and inv(16) mutation can not be used as prognostic factors for complete remission after induction phase of chemotherapy in pediatric AML.

References

1. Jaime-Pérez JC, Padilla-Medina JR, Fernández LT, Herrera-Garza JL, Gutiérrez-Aguirre CH, Tarín-Arzaga L, et al. Outcomes of adolescents and young adults with acute myeloid leukemia treated in a single Latin American Center. Clin Lymphoma, Myeloma Leuk. 2018;18:286–92. DOI: 10.1016/j.clml.2018.02.002.
2. JE R. Current management of childhood acute myeloid leukemia. Paediatr Drugs. 2017;19:1-10. DOI: 10.1007/s40272-016-0200-6
3. Mansoor N, Jabbar N, Arshad U, Maqsood S, Habib MA, Raza MR. Outcome of core binding factor acute myeloid leukemia in children: A single-center experience. J Pediatr Hematol Oncol. 2020;42:E423–7. DOI: 10.1097/mph.0000000000001853.
4. Jastaniah, Alsultan A, Daama S Al, Ballourah W, Bayoumy M, Al-Anzi F, et al. Is the outcome of childhood acute myeloid leukemia with t(8;21) inferior in Saudi Arabia? A multicenter SAPHOS leukemia group study. J Appl Hematol. 2017;8:41. DOI: 10.4103/joah.joah_16_17.
5. Jastaniah W, Bayoumy M, Alsultan A, Al Daama S, Ballourah W, Al-Anzi F, et al. Identifying prognostic factors that influence outcome of childhood acute myeloid leukemia in first relapse in Saudi Arabia: results of the multicenter SAPHOS Study. Clin Lymphoma Myeloma Leuk. 2018;18:773–80. DOI: 10.1016/j.clml.2018.09.001.
6. So CC, Wan TS, Chow JL, Hui KC, Choi WW, Lam CC, et al. A single-center cytogenetic study of 629 Chinese patients with de novo acute myeloid leukemia—evidence of major ethnic differences and a high prevalence of acute promyelocytic leukemia in Chinese patients. Cancer Genet. 2011;204:430–8. DOI: 10.1016/j.cancergen.2011.06.003.
7. Horibe K, Tsukimoto I, Ohno R. Clinicopathologic characteristics of leukemia in Japanese children and young adults. Leukemia. 2001;15:1256–61. DOI: 10.1038/sj.leu.2402194.
8. Amare PSK, Jain H, Kabre S, Deshpande Y, Pawar P, Banavali S, et al. Cytogenetic profile in 7209 Indian patients with de novo acute leukemia: a single centre study from India. J Cancer Ther. 2016;7:530–44. DOI: 10.4236/jct.2016.77056.
9. Tyagi A, Pramanik R, Chaudhary S, Chopra A, Bakhshi S. Cytogenetic profiles of 472 indian children with acute myeloid leukemia. Indian Pediatr. 2018;55:469-73. PMID: 29978812.
10. Pession A, Masetti R, Rizzari C, Putti MC, Casale F, Fagioli F, Luciani M, Lo Nigro L, Menna G, Micalizzi C, Santoro N. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood, The Journal of the American Society of Hematology. 2013;122:170-8. DOI: 10.1182/blood-2013-03-491621.
11. Kiem Hao T, Van Ha C, Huu Son N, Nhu Hiep P. Long-term outcome of childhood acute myeloid leukemia: a 10-year retrospective cohort study. Pediatric reports. 2020;12:22-5. DOI: 10.4081/pr.2020.8486.
12. Ghafoor T, Ahmed S, Khalil S, Farah T. Optimum induction chemotherapy for pediatric acute myeloid leukemia: experience from a developing country. The Journal of Pediatric Pharmacology and Therapeutics. 2020;25:288-94. DOI: 10.5863/1551-6776-25.4.288
13. Sjakti HA, Gatot D, Windiastuti E. Hasil pengobatan leukemia mieloblastik akut pada anak. Sari Pediatri. 2012;14:40-5. DOI: 10.14238/sp14.1.2012.40-5.
14. Zhai XW, Cheng FW, Lee V, Leung WK, Ng MH, Tsang KS, Shing MK, Li CK. Improved survival outcome of childhood acute myeloid leukemia with intensified chemotherapy in Chinese children. Pediatr Hematol Oncol. 2011;28:269-78. DOI: 10.3109/08880018.2010.533249.
15. Jastaniah W, Al Ghemlas I, Al Daama S, Ballourah W, Bayoumy M, Al-Anzi F, et al. Clinical characteristics and outcome of childhood de novo acute myeloid leukemia in Saudi Arabia: A multicenter SAPHOS leukemia group study. Leuk Res. 2016;49:66–72. DOI: 10.1016/j.leukres.2016.08.009.